STAT

STAT+: In surprise decision, FDA rejects radiopharma therapy expected to rival Novartis treatment

STAT+: In surprise decision, FDA rejects radiopharma therapy expected to rival Novartis treatmentWorldPing

The FDA has rejected a radiopharmaceutical therapy because of manufacturing issues, halting what would have been a competitor for Novartis.

This is a short WorldPing brief. The full report was published by STAT.

Read the full report at STAT

Related news

TechCrunch

Archer buys former rival Wisk Aero

The two companies were once embroiled in a trade secret theft lawsuit. Now, Wisk is being absorbed into Archer.

Brief by WorldPing · Original reporting by TechCrunch